Get access

Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.

  • Protocol
  • Intervention


  • DK Cundiff,

  • J Manyemba

Dr David Cundiff, 319 Grand Avenue, Long Beach, CA, 90814, USA.


This is the protocol for a review and there is no abstract. The objectives are as follows:

To examine the existing clinical evidence of the effect of anticoagulants (heparins and vitamin K antagonists) versus placebo or anti-inflammatory drugs in patients with VTE on the incidence of fatal and non-fatal pulmonary emboli (PE), and the recurrence/extension of deep vein thrombosis (DVT).

Secondly, to evaluate the risks of anticoagulant therapy for venous thromboembolism (VTE), including all major bleeding events and anticoagulant-induced clotting (heparin-induced-thrombocytopenia (HIT) and warfarin necrosis). The following hypotheses will be tested:
(a) That treatment with anticoagulants reduces the incidence of fatal PE in patients with DVT and/or PE when compared with placebo or anti-inflammatory drugs.
(b) That the benefit of treating VTE with anticoagulants outweighs the risk of death due to complications of anticoagulant treatment.